Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutic Products Using Silence’s mRNAi GOLD ™ Platform
Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutic Products Using Silence’s mRNAi GOLD â¢ Platform
Hansoh will make a $ 16 million in advance cash payment and Silence has the potential to receive Up to $ 1.3 billion in milestones
Silence wins exclusive rights of of them targets in all territories except the China Region; Hansoh To rights to edare two targets in the China region and global rights on a third target
October 15, 2021
LONDON and SHANGHAI, Silence Therapeutics plc (AIM: SLN and Nasdaq: SLN), a leader in the discovery, development and delivery of new therapeutics based on short interfering ribonucleic acid (siRNA) for the treatment of diseases presenting a significant unmet medical need, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, 3692.HK), one of the leading biopharmaceutical companies in China, today announced a collaboration to develop siRNAs for three undisclosed targets in based on Silence’s exclusive mRNAi GOLD â¢ platform.
Under the terms of the agreement, Hansoh will have the exclusive option to license the rights to the first two targets in Greater China, Hong Kong, Macau and Taiwan after completion of the Phase 1 studies. Silence will retain the exclusive rights of these two targets in all other territories. Silence will be responsible for all activities until the option is exercised and will retain responsibility for development outside the China region after Phase 1 studies.
Hansoh will also have the exclusive option to license the worldwide rights to a third target at the time of the IND filing. Hansoh will be responsible for all development activities after the exercise of options for the third target.
Hansoh will make an upfront payment of $ 16 million and Silence is eligible to receive up to $ 1.3 billion of additional development, regulatory and commercial milestones. Silence will also receive tiered royalties from low to double digit to mid-teenager on net sales of Hansoh products.
Mark Rothera, President and CEO of Silence Therapeutics, noted: âWe believe Hansoh’s extensive clinical development and commercialization experience in China makes it an ideal partner. This collaboration is a good example of our hybrid model in action, balancing proprietary and partnered programs to maximize the substantial opportunity of our GOLD â¢ mRNA platform to target disease-associated genes in the liver. The Hansoh partnership allows us to advance two new proprietary programs funded by non-dilutive capital while accessing the second largest pharmaceutical market in the world. We look forward to discussing this deal and our broader pipeline in more detail during our next R&D day on October 21.st At New York.”
Eliza Sun, Executive Director of the Board of Hansoh Pharma, said: âWe are delighted to partner with Silence, a pioneer in the therapeutic development of siRNAs with decades of scientific and technical experience. As one of the largest biopharmaceutical companies in China, Hansoh strives to partner with innovative companies globally to develop and advance our strong pipeline spanning multiple therapeutic areas. We see a substantial opportunity in Silence’s mRNAi GOLD â¢ platform to develop and deliver better, precision-based drugs to patients in China and around the world.
Silence Therapeutics plc
Gem Hopkins, Head of International Relations and Corporate Communications
Phone. : +1 (646) 637-3208
Investec Bank plc (Advisor and designated broker)
Daniel Adams / Gary Clarence
Phone: +44 (0) 20 7597 5970
Consilium Strategic communication
Mary-Jane Elliott / Chris Welsh / Angela Gray
Phone: +44 (0) 20 3709 5700
Dr. Sophia Dong, Director of Investor Relations
On Hansoh Pharmacy
Hansoh Pharma (3692.HK), One of Greater China and Asia’s Largest Biopharmaceutical Companies, Committed to Discovering and Developing Patient-Life-Changing Drugs to Help Patients Beat Diseases and serious disorders. Hansoh Pharma is supported by more than 12,000 dedicated employees in China and the United States. Founded in 1995, Hansoh has fully integrated research and development, manufacturing and marketing capabilities, supporting leading positions in a wide range of therapeutic areas, including oncology, central nervous system (CNS) disorders, infectious diseases, cardiovascular diseases, diabetes and autoimmune diseases. diseases. With the support of over 1,600 highly skilled R&D professionals, Hansoh has successfully developed several drug candidates discovered in-house for innovative NMPA-approved drugs, including aumolertinib (é¿ å å Â®), an inhibitor of NMPA. Third generation EGFR for the treatment of NSCLC with EGFR mutations. , flumatinib (æ ç¦ Â®), a second generation BCR-ABL inhibitor for the first-line treatment of chronic myelogenous leukemia (CML), PEG-loxenatide (å æ¥ ç¾ Â®), the first analogue of GLP- 1 long-acting once weekly discovered and developed in China for the treatment of diabetes, morinidazole (è¿ çµ è¾¾ Â®), a third generation nitroimidazole antibiotic and tenofovir amibufenamide (æ æ² Â®), the first anti-HBV drug second generation oral developed in China. For more information, please visit www.hspharm.com.
About Silence Therapeutics
Silence Therapeutics is developing a new generation of drugs by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes believed to play a role in the pathology of diseases with high unmet needs. Silence’s proprietary mRNAi GOLD â¢ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, representing a substantial opportunity. Silence’s wholly owned product candidates include SLN360 designed to address the high and widespread unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a) and SLN124 designed to treat conditions of anemia. iron. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.
Certain statements made in this announcement are forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and other securities laws, including with respect to the Company’s clinical and business prospects and timing. planned data reports from testing laboratories. These forward-looking statements are not historical facts but are rather based on the Company’s current expectations, estimates and projections regarding its industry; his beliefs; and assumptions. Words such as “anticipates”, “expects”, “intends”, “plans”, “believes”, “research”, “estimates” and similar expressions are intended to identify forward-looking statements. . These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of the Company, are difficult to predict and could cause actual results differ materially from those expressed or expected. in forward-looking statements, including the risks identified in the Company’s most recent admission document and its amended annual report on Form 20-F filed with the United States Securities and Exchange Commission on April 29, 2021. The Company cautions holders of securities and potential holders of securities not to place undue reliance on these forward-looking statements, which reflect the views of the Company only as of the date of this announcement. The forward-looking statements contained in this announcement relate only to events that occurred on the date on which the statements are made. The Company will not undertake to publicly post revisions or updates to these forward-looking statements to reflect unforeseen events, circumstances or events occurring after the date of this announcement, except as required by law or by any authority. appropriate regulatory framework.